Skip to main content
. 2018 Feb 5;6:24–28. doi: 10.1016/j.biopen.2018.01.001

Fig. 2.

Fig. 2

Currents observed in M3R and M3R + NALCN/Unc80/Src cells exhibited similar properties to currents observed in untransfected cells and eGFP transfected cells. (A) The amplitude of the current at +20 mV before and after application of muscarinic receptor agonist (muscarine iodide or Oxo-M) at 100 μM for all cells tested. There was a significant main effect between the current amplitude before and after agonist (within-subject effect in a two-way mixed-design ANOVA, DF = 1, p = 7.0 × 10−7, followed by Bonferroni post hoc tests; where * indicates p < 0.05). There were no significant differences between the current amplitudes of untransfected, eGFP, M3R or M3R + NALCN/Unc80/Src cells (between subject effects; DF = 3, p = 0.53). (B) The amplitude of the current at +20 mV before and after application of muscarinic receptor agonist (muscarine iodide or Oxo-M) at 100 μM for only responsive cells. There was a significant main effect between the current amplitude before and after agonist (within-subject effect in a two-way mixed-design ANOVA, DF = 1, p = 9.1 × 10−6, followed by Bonferroni post hoc tests; where * indicates p < 0.05). There were no significant differences between the current amplitudes of untransfected, eGFP, M3R or M3R + NALCN/Unc80/Src cells (between subject effects; DF = 3, p = 0.55). (C) Percentage of untransfected, eGFP, M3R and M3R + NALCN/Unc80/Src cells considered responsive to muscarinic receptor agonist application were not significantly different (p = 0.51, Chi-square test). (D) Mean reversal potentials for currents elicited from responsive untransfected, eGFP, M3R and M3R + NALCN/Unc80/Src cells were not significantly different (p = 0.49, one way ANOVA). All error bars represent ±SEM.